The research includes the synthesis of novel heterocyclic compounds for their evaluation as inhibitors of MYC oncoprotein through inhibition of MYC-MAX dimerization.  Inhibition of the specific protein is crucial for the development of therapeutic methods against cancer, because of its major impact to the development of cancer cells, such as those of pancreatic adenocarcinoma and other cancers. The research uses heterocyclic molecules as lead-compounds, the modifications of which include variation of their substituents, addition of different groups and changes in the basic heterocyclic core, in order to optimize their activity, based on computer-aided design. Part of the new designed analogues are synthesized in the Natural Products and Bioorganic Chemistry Laboratory of the Institute of Nanoscience & Nanotechnology, under the supervision of Dr V. Vidali, funded as subcontractor by the Biomedical Research Foundation, Academy of Athens as part of the Research Grant "Development of novel anticancer drugs with therapeutic target the oncoprotein MYC" (MIS-5031813) funded by the Operational Program Competitiveness, Entrepreneurship and Innovation (NSRF 2014-2020) co-financed by Greece and the European Union.